Cargando…
The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function
New technologies may displace existing, higher‐value care under a fixed budget. Countries aim to curtail adoption of low‐value technologies, for example, by installing cost‐effectiveness thresholds. Our objective is to estimate the opportunity cost of hospital care to identify a threshold value for...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851736/ https://www.ncbi.nlm.nih.gov/pubmed/31469510 http://dx.doi.org/10.1002/hec.3946 |
_version_ | 1783469674818699264 |
---|---|
author | Stadhouders, Niek Koolman, Xander van Dijk, Christel Jeurissen, Patrick Adang, Eddy |
author_facet | Stadhouders, Niek Koolman, Xander van Dijk, Christel Jeurissen, Patrick Adang, Eddy |
author_sort | Stadhouders, Niek |
collection | PubMed |
description | New technologies may displace existing, higher‐value care under a fixed budget. Countries aim to curtail adoption of low‐value technologies, for example, by installing cost‐effectiveness thresholds. Our objective is to estimate the opportunity cost of hospital care to identify a threshold value for the Netherlands. To this aim, we combine claims data, mortality data and quality of life questionnaires from 2012 to 2014 for 11,000 patient groups to obtain quality‐adjusted life‐year (QALY) outcomes and spending. Using a fixed effects translog model, we estimate that a 1% increase in hospital spending on average increases QALY outcomes by 0.2%. This implies a threshold of €73,600 per QALY, with 95% confidence intervals ranging from €53,000 to €94,000 per QALY. The results stipulate that new technologies with incremental cost effectiveness ratios exceeding the Dutch upper reference value of €80,000 may indeed displace more valuable care. |
format | Online Article Text |
id | pubmed-6851736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68517362019-11-18 The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function Stadhouders, Niek Koolman, Xander van Dijk, Christel Jeurissen, Patrick Adang, Eddy Health Econ Research Articles New technologies may displace existing, higher‐value care under a fixed budget. Countries aim to curtail adoption of low‐value technologies, for example, by installing cost‐effectiveness thresholds. Our objective is to estimate the opportunity cost of hospital care to identify a threshold value for the Netherlands. To this aim, we combine claims data, mortality data and quality of life questionnaires from 2012 to 2014 for 11,000 patient groups to obtain quality‐adjusted life‐year (QALY) outcomes and spending. Using a fixed effects translog model, we estimate that a 1% increase in hospital spending on average increases QALY outcomes by 0.2%. This implies a threshold of €73,600 per QALY, with 95% confidence intervals ranging from €53,000 to €94,000 per QALY. The results stipulate that new technologies with incremental cost effectiveness ratios exceeding the Dutch upper reference value of €80,000 may indeed displace more valuable care. John Wiley and Sons Inc. 2019-08-30 2019-11 /pmc/articles/PMC6851736/ /pubmed/31469510 http://dx.doi.org/10.1002/hec.3946 Text en © 2019 The Authors. Health Economics published by John Wiley & Sons, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Stadhouders, Niek Koolman, Xander van Dijk, Christel Jeurissen, Patrick Adang, Eddy The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function |
title | The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function |
title_full | The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function |
title_fullStr | The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function |
title_full_unstemmed | The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function |
title_short | The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function |
title_sort | marginal benefits of healthcare spending in the netherlands: estimating cost‐effectiveness thresholds using a translog production function |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851736/ https://www.ncbi.nlm.nih.gov/pubmed/31469510 http://dx.doi.org/10.1002/hec.3946 |
work_keys_str_mv | AT stadhoudersniek themarginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction AT koolmanxander themarginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction AT vandijkchristel themarginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction AT jeurissenpatrick themarginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction AT adangeddy themarginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction AT stadhoudersniek marginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction AT koolmanxander marginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction AT vandijkchristel marginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction AT jeurissenpatrick marginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction AT adangeddy marginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction |